MSB Trading - 2019, page-1243

Hi all,

I met SI today at Bellpotter as he did a presentation for all brokers/clients that were interested. Although he is now worth a lot of money since listing on the ASX/NASDAQ he didn't seem cocky in his demeanor nor seem disinterested in further growing the company. A few notes that i thought were quite important to influence the SP are;
- He is anticipating a Q1CY20 launch of GvHD, he believes there is a 90% chance of the FDA approving the submission, the only reason he leaves that extra 10% is due to the potential that not all information is presented in the submission which would be a monumental ****up if that happens. MSB are going to sell and distribute the product if approved themselves (although the FDA has 6 months to deliberate once the submission is completed so could be unlikely pushed out to Q2)
- Heart Failure: SI is meeting with the FDA this month to discuss the Phase 3, GI bleeding trial should be finished in Q4CY19 with results published in Q1CY20. This will lead onto the submission of the LVAD FDA submission, with the results to benefit both products. They will need a partner to take advantage of their distribution channels to commercialise this product. Something which he suggested will be looked into closer to the submission to the FDA.
- Chronic Back Pain: only briefly touched on this, however he also said the phase 3 results are set to be sorted in Q1CY20. Big market as the product can be tailored to be used on knees and other body parts susceptible to sports injuries.

Seems like we will be tracking sideways till start of 2020 but I hope there is more news before then!!!

DYOR

GLTAH